-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GTX-102 in Angelman Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GTX-102 in Angelman Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GTX-102 in Angelman Syndrome Drug Details: GTX-102 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexigebersen in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexigebersen in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexigebersen in Refractory Acute Myeloid Leukemia Drug Details: Prexigebersen (BP-1001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexigebersen in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexigebersen in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexigebersen in Relapsed Acute Myeloid Leukemia Drug Details: Prexigebersen (BP-1001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexigebersen in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prexigebersen in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prexigebersen in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ION-859 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ION-859 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ION-859 in Parkinson's Disease Drug Details: ION-859 (IONISBIIB-7Rx) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bepirovirsen Sodium in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bepirovirsen Sodium in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bepirovirsen Sodium in Hepatitis B Drug Details: IONIS-HBVRx (ISIS-HBVRx, ISIS-GSK3Rx) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ION-464 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ION-464 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ION-464 in Multiple System...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-1102 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-1102 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-1102 in Duchenne Muscular Dystrophy Drug Details: ATL-1102, (TV-1102, ISIS 107248)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ION-547 in Thrombosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ION-547 in Thrombosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ION-547 in Thrombosis Drug Details: ION-547 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SPL-84 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPL-84 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPL-84 in Cystic Fibrosis Drug Details: SPL84-23-1 is under development for the...